Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy
AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of the study is to determine the maximally tolerated dose, the pharmacokinetics, and the toxicity of the drug on the designated schedule.
Neoplasm Metastasis
DRUG: imexon
Determine the maximally tolerated dose|determine the pharmacokinetics|determine the toxicity of the drug on the designated schedule
AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of the study is to determine the maximally tolerated dose, the pharmacokinetics, and the toxicity of the drug on the designated schedule.